GlassScriptPhysician profile
Cassidy M Dickson
NPI 1609333947
$4,139.14
in general payments reported to CMS, 2019-2025
27 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.96 · 2022: $13.43 · 2023: $1,228 · 2024: $1,884 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,014 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,013.76 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,151.22 | 2023-2025 | |
| Janssen Biotech, INC. | $501.45 | 2023-2025 | Stelara, Tremfya |
| Genzyme Corporation | $389.67 | 2023-2025 | |
| Gilead Sciences, INC. | $289.08 | 2023-2025 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.09 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Qol Medical, LLC | $177.76 | 2023-2024 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $163.24 | 2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $157.34 | 2023-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $132.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $130.90 | 2023-2025 | Dupixent |
| Axonics, INC. | $130.35 | 2023-2024 | Axonics, Bulkamid |
| Celgene Corporation | $127.27 | 2023-2024 | Zeposia |
| Celltrion USA INC. | $106.09 | 2025 | Vegzelma |
| Ardelyx, INC. | $85.56 | 2023-2024 | Ibsrela |
| Evoke Pharma, INC. | $76.94 | 2023-2025 | Gimoti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $70.75 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $52.40 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $37.89 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $30.21 | 2023-2025 | Ocaliva |
| Pfizer INC. | $29.62 | 2024-2025 | |
| Mylan Institutional INC. | $22.16 | 2023 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.28 | 2023 | Cyltezo |
| Novo Nordisk INC | $19.69 | 2025 | Wegovy |
| Medtronic, INC. | $18.94 | 2024 | Interstim |
| Boston Scientific Corporation | $14.53 | 2025 | Axonics |
| Janssen Pharmaceuticals, INC | $13.43 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassidy Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.